血清CEA、CA125及Cyfra21-1水平对中晚期非小细胞肺癌患者预后的影响
DOI: 10.3971/j.issn.1000-8578.2016.02.009
Keywords: A Meta-analysis,Research Progress of circRNAs in Cancer,NSCLC的疫苗治疗研究进展,Advances of FGF/FGFR Signaling Pathway in Targeted Therapy for Squamous Cell Lung Cancer,Effect of Vascular Endothelial Cadherin on Invasion and Metastasis of Non-small Cell Lung Cancer Cells and Related Mechanism,Clinical Investigation on Qingfei Mixture Combined with Chemotherapy on Middle and Advanced Non-small Cell Lung Cancer,Prognosis of Clinical Stage ⅢA(N2) Non-small Cell Lung Cancer Patients Received Radiotherapy,Application of 18F-FDG PET/CT in Follow-up of Primary Breast Cancer Patients with Increased Serum CEA and(or) CA153,Quality Assessment of Reports of Randomized Controlled Trials Published in Chinese in Field of Non-small Cell Lung Cancer in China,Review of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Adjuvant Treatment of Non-small Cell Lung Cancer,Evaluation of Ligand-targeted PCR Method in Detecting Tumor Cell Levels in Pleural Effusion of Patients with Non-small Cell Lung Cancer,Association of Cytochrome P450 2E1-1239G>C Genetic Variation with Prognosis of Metastatic Non-small Cell Lung Cancer Patients,HOXB7 Regulates Proliferation of Non-small Cell Lung Cancer Cell A549
Abstract:
摘要 目的 探讨晚期非小细胞肺癌（NSCLC） 患者血清癌胚抗原（CEA） 、糖类抗原（CA125）、非小细胞肺癌相关抗原（Cyfra21-1）水平与无疾病进展生存期的相关性。方法 选取2012年6月至2014年5月于宜昌市第二人民医院确诊的非小细胞肺癌患者120例，对其临床资料进行回顾性分析，了解CEA、CA125、Cyfra21-1水平与无疾病进展生存期的相关性。结果 与鳞癌患者相比，血清CEA水平在肺腺癌患者中明显升高（P＜0.05）；血清CA125水平在Ⅳ期肺腺癌患者中明显升高（P＜0.05）；血清Cyfra21-1在患者疾病一般特征中差异未见统计学意义（P＞0.05）。血清CEA、CA125、Cyfra21-1水平升高的患者中位无疾病进展生存期分别为4.2、4.5、4.3月，与正常组相比差异均有统计学意义（P＜0.05）。结论 晚期非小细胞肺癌患者CEA、CA125、Cyfra21-1升高与无疾病进展生存期存在明显的相关性，临床医师可通过检测患者血清CEA、CA125、Cyfra21-1水平判断预后
Full-Text
